ArticleFrontiers in oncology2025

Single-agent rituximab and ultra-low-dose adaptive radiotherapy for the treatment of indolent B-cell non-Hodgkin lymphomas.

Katherine E Lake et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.